http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 15:27:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26929504.html si-local-file:///var/storage/secattach/20260814/26929504.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26929504.html Fri, 14 Aug 2026 15:27:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26929504.html si-local-file:///var/storage/secattach/20260814/26929504.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26929504.html Fri, 14 Aug 2026 15:27:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Corporate+News/Exicure+to+issue+shares+worth+%241M+to+settle+milestone+payment/26855150.html <p>Exicure, Inc. (Nasdaq: XCUR) plans to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under a License and Collaboration Agreement between the two parties.</p><p>The milestone was triggered by the completion of a Phase 2 clinical trial of Burixafor (GPC-100), which included the formal submission of a Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p><p>The shares are expected to be issued at a deemed value of $5.81 per share, based on applicable Nasdaq trading data, representing an aggregate deemed value of http://www.streetinsider.com/Corporate+News/Exicure+to+issue+shares+worth+%241M+to+settle+milestone+payment/26855150.html Mon, 03 Aug 2026 09:25:05 -0400 XCUR http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html <p align="justify">WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement.</p> <p align="justify">The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Exicure+to+Settle+GPCR+Therapeutics+Clinical+Milestone+Payment+Through+Equity+Issuance/26855147.html Mon, 03 Aug 2026 09:24:00 -0400 A.06822034 O.20026344 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+23++Filed+by%3A+Exicure+HiTron+Inc./26784815.html si-local-file:///var/storage/secattach/20260717/26784815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+23++Filed+by%3A+Exicure+HiTron+Inc./26784815.html Fri, 17 Jul 2026 16:39:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+23++Filed+by%3A+Exicure+HiTron+Inc./26784815.html si-local-file:///var/storage/secattach/20260717/26784815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+23++Filed+by%3A+Exicure+HiTron+Inc./26784815.html Fri, 17 Jul 2026 16:39:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++EXICURE%2C+INC.++++++++++++++++++++++++++Filed+by%3A+Exicure+HiTron+Inc./26783509.html si-local-file:///var/storage/secattach/20260717/26783509.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++EXICURE%2C+INC.++++++++++++++++++++++++++Filed+by%3A+Exicure+HiTron+Inc./26783509.html Fri, 17 Jul 2026 13:06:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++EXICURE%2C+INC.++++++++++++++++++++++++++Filed+by%3A+Exicure+HiTron+Inc./26783509.html si-local-file:///var/storage/secattach/20260717/26783509.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++EXICURE%2C+INC.++++++++++++++++++++++++++Filed+by%3A+Exicure+HiTron+Inc./26783509.html Fri, 17 Jul 2026 13:06:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26712984.html si-local-file:///var/storage/secattach/20260630/26712984.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26712984.html Tue, 30 Jun 2026 14:56:00 -0400 O.31702753 XCUR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26712984.html si-local-file:///var/storage/secattach/20260630/26712984.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EXICURE%2C+INC.+++++++++++++For%3A+Jun+30/26712984.html Tue, 30 Jun 2026 14:56:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Board+Changes/Exicure+names+two+new+board+directors%2C+expands+board+to+six/26710336.html <p>Exicure, Inc. (Nasdaq: XCUR) announced changes to its board of directors, effective June 30, 2026, following actions approved at a special board meeting held June 24, 2026.</p><p>The board accepted the resignation of Jung Kyu Ham as a director. Jin Young Go was appointed as a Class III director to fill the vacancy left by Ham's departure. The board also approved expanding its size from five to six directors and appointed Eui Seok Han as an additional Class III director to fill the newly created seat.</p><p>The board determined that Eui Seok Han qualifies as an independent director under Nasdaq listing rules. http://www.streetinsider.com/Board+Changes/Exicure+names+two+new+board+directors%2C+expands+board+to+six/26710336.html Tue, 30 Jun 2026 08:40:59 -0400 XCUR http://www.streetinsider.com/Corporate+News/Exicure+names+two+new+board+directors%2C+expands+board+to+six/26710336.html <p>Exicure, Inc. (Nasdaq: XCUR) announced changes to its board of directors, effective June 30, 2026, following actions approved at a special board meeting held June 24, 2026.</p><p>The board accepted the resignation of Jung Kyu Ham as a director. Jin Young Go was appointed as a Class III director to fill the vacancy left by Ham's departure. The board also approved expanding its size from five to six directors and appointed Eui Seok Han as an additional Class III director to fill the newly created seat.</p><p>The board determined that Eui Seok Han qualifies as an independent director under Nasdaq listing rules. http://www.streetinsider.com/Corporate+News/Exicure+names+two+new+board+directors%2C+expands+board+to+six/26710336.html Tue, 30 Jun 2026 08:40:59 -0400 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Board+and+Committee+Changes/26710324.html <p>WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (&quot;Exicure&quot; or the &quot;Company&quot;) today announced changes to its Board of Directors and Board committees following actions approved by the Company&apos;s Board of Directors at its special meeting held on June 24, 2026.</p> <p>The Company&apos;s Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.</p> <p>The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham&apos;s resignation. In addition, the Board approved an increase in the size of http://www.streetinsider.com/Press+Releases/Exicure+Announces+Board+and+Committee+Changes/26710324.html Tue, 30 Jun 2026 08:40:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Board+and+Committee+Changes/26710324.html <p>WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (&quot;Exicure&quot; or the &quot;Company&quot;) today announced changes to its Board of Directors and Board committees following actions approved by the Company&apos;s Board of Directors at its special meeting held on June 24, 2026.</p> <p>The Company&apos;s Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.</p> <p>The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham&apos;s resignation. In addition, the Board approved an increase in the size of http://www.streetinsider.com/Press+Releases/Exicure+Announces+Board+and+Committee+Changes/26710324.html Tue, 30 Jun 2026 08:40:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Board+and+Committee+Changes/26710324.html <p>WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (&quot;Exicure&quot; or the &quot;Company&quot;) today announced changes to its Board of Directors and Board committees following actions approved by the Company&apos;s Board of Directors at its special meeting held on June 24, 2026.</p> <p>The Company&apos;s Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.</p> <p>The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham&apos;s resignation. In addition, the Board approved an increase in the size of http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Board+and+Committee+Changes/26710324.html Tue, 30 Jun 2026 08:40:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Board+and+Committee+Changes/26710324.html <p>WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (&quot;Exicure&quot; or the &quot;Company&quot;) today announced changes to its Board of Directors and Board committees following actions approved by the Company&apos;s Board of Directors at its special meeting held on June 24, 2026.</p> <p>The Company&apos;s Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.</p> <p>The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham&apos;s resignation. In addition, the Board approved an increase in the size of http://www.streetinsider.com/Globe+Newswire/Exicure+Announces+Board+and+Committee+Changes/26710324.html Tue, 30 Jun 2026 08:40:00 -0400 O.31702753 XCUR http://www.streetinsider.com/Corporate+News/Exicure+receives+NASDAQ+notice+for+failing+equity+requirement/26629724.html <p>Exicure Inc. (NASDAQ: XCUR) received a notification from NASDAQ on June 5 stating the company does not meet the minimum stockholders' equity requirement of $2.5 million for continued listing on The NASDAQ Capital Market.</p><p>The biotechnology company reported stockholders' equity of approximately $2.1 million in its quarterly report for the period ended March 31, 2026. NASDAQ also determined that Exicure does not satisfy alternative listing standards related to market value of listed securities or net income from continuing operations.</p><p>The notification does not immediately affect the listing of Exicure's common stock. Under NASDAQ rules, the company has 45 calendar days until July http://www.streetinsider.com/Corporate+News/Exicure+receives+NASDAQ+notice+for+failing+equity+requirement/26629724.html Wed, 10 Jun 2026 16:01:55 -0400 XCUR http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Notice+Regarding+Minimum+Stockholders%E2%80%99+Equity+Requirement/26629710.html <p>WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity.</p> <p>As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company reported stockholders’ equity of approximately $2.1 million. Nasdaq http://www.streetinsider.com/Press+Releases/Exicure+Announces+Receipt+of+Nasdaq+Notice+Regarding+Minimum+Stockholders%E2%80%99+Equity+Requirement/26629710.html Wed, 10 Jun 2026 16:01:00 -0400 A.50216776 O.29783969 O.31702753 XCUR